APA (7th ed.) Citation

C, B., S, G., G, P., C, B., M, C., L, T., . . . M, M. (2020). The switch from etanercept originator to SB4: Data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Therapeutic advances in musculoskeletal disease, 12, 1759720X20964031. https://doi.org/10.1177/1759720X20964031

Chicago Style (17th ed.) Citation

C, Bruni, et al. "The Switch from Etanercept Originator to SB4: Data from a Real-life Experience on Tolerability and Persistence on Treatment in Joint Inflammatory Diseases." Therapeutic Advances in Musculoskeletal Disease 12 (2020): 1759720X20964031. https://doi.org/10.1177/1759720X20964031.

MLA (9th ed.) Citation

C, Bruni, et al. "The Switch from Etanercept Originator to SB4: Data from a Real-life Experience on Tolerability and Persistence on Treatment in Joint Inflammatory Diseases." Therapeutic Advances in Musculoskeletal Disease, vol. 12, 2020, p. 1759720X20964031, https://doi.org/10.1177/1759720X20964031.